Evidence map›Paper›PMID 37133429›Full record

Observational studyJournal of managed care & specialty pharmacy2023

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.

Sanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, Erin K Buysman, Brendan Clark, Andrew Sargent, Asif Shaikh, Gary T Ferguson

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Burden of Exacerbations in Patients Newly Initiating an Inhaled Regimen for COPD: A Claims Analysis.International journal of chronic obstructive pulmonary disease · 2025
    Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Sanjay SethiJacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY.
Swetha R PalliBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Lindsay G S BengtsonOptum Life Sciences, Eden Prairie, MN.
Erin K BuysmanOptum Life Sciences, Eden Prairie, MN.
Brendan ClarkBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Andrew SargentOptum Life Sciences, Eden Prairie, MN.
Asif ShaikhBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Gary T FergusonDepartment of Medicine, Pulmonary Research Institute of Southeast Michigan, Farmington Hills.
Boehringer Ingelheim (United States) · USOptum (United States) · USJacobs Institute · USMichigan Ear Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adrenergic beta-2 Receptor AgonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAndrostadienesBenzoxazinesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesHumansMaleMuscarinic AntagonistsQuinuclidinesTiotropium BromideAdrenergic beta-2 Receptor AgonistsAndrostadienesBenzoxazinesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesfluticasone furoateGSK573719Muscarinic AntagonistsolodaterolQuinuclidinesTiotropium Bromidevilanterol

Identifiers

PMID37133429
PMCPMC10394184
OpenAlexW4367834884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.